TY - JOUR
T1 - Myosteatosis in NAFLD patients correlates with plasma Cathepsin D
AU - Ding, Lingling
AU - De Munck, Toon J I
AU - Oligschlaeger, Yvonne
AU - Dos Reis, Inês Magro
AU - Verbeek, Jef
AU - Koek, Ger H
AU - Houben, Tom
AU - Shiri-Sverdlov, Ronit
N1 - © 2021 Lingling Ding et al., published by De Gruyter.
PY - 2021/5/15
Y1 - 2021/5/15
N2 - Previously, we have shown that hepatic lipid accumulation induces the secretion of cathepsin D (CTSD), and that plasma CTSD levels are associated with increased inflammation and disease severity in nonalcoholic fatty liver disease (NAFLD). Although it is clear that the liver is a major source of plasma CTSD, it is unknown whether other metabolically active organs such as the muscle, also associate with plasma CTSD levels in NAFLD patients. Therefore, the aim of this study was to explore the relation between lipid accumulation in the muscle (myosteatosis) and plasma CTSD levels in forty-five NAFLD patients. We observed that hepatic steatosis positively associated with plasma CTSD levels, confirming the previously established link between plasma CTSD and the liver. Furthermore, a positive association between myosteatosis and plasma CTSD levels was observed, which was independent of sex, age, BMI, waist circumference and hepatic steatosis. By establishing a positive association between myosteatosis and plasma CTSD levels, our findings suggest that, in addition to the liver, the muscle is also linked to plasma CTSD levels in NAFLD patients. The observed link between myosteatosis and plasma CTSD levels supports the concept of a significant role of the skeletal muscle in metabolic disturbances in metabolic syndrome-related disorders.
AB - Previously, we have shown that hepatic lipid accumulation induces the secretion of cathepsin D (CTSD), and that plasma CTSD levels are associated with increased inflammation and disease severity in nonalcoholic fatty liver disease (NAFLD). Although it is clear that the liver is a major source of plasma CTSD, it is unknown whether other metabolically active organs such as the muscle, also associate with plasma CTSD levels in NAFLD patients. Therefore, the aim of this study was to explore the relation between lipid accumulation in the muscle (myosteatosis) and plasma CTSD levels in forty-five NAFLD patients. We observed that hepatic steatosis positively associated with plasma CTSD levels, confirming the previously established link between plasma CTSD and the liver. Furthermore, a positive association between myosteatosis and plasma CTSD levels was observed, which was independent of sex, age, BMI, waist circumference and hepatic steatosis. By establishing a positive association between myosteatosis and plasma CTSD levels, our findings suggest that, in addition to the liver, the muscle is also linked to plasma CTSD levels in NAFLD patients. The observed link between myosteatosis and plasma CTSD levels supports the concept of a significant role of the skeletal muscle in metabolic disturbances in metabolic syndrome-related disorders.
KW - Adult
KW - Aged
KW - Cathepsin D/blood
KW - Female
KW - Fibrosis/blood
KW - Humans
KW - Male
KW - Middle Aged
KW - Muscle, Skeletal/metabolism
KW - Non-alcoholic Fatty Liver Disease/physiopathology
KW - Sarcopenia/blood
KW - Young Adult
U2 - 10.1515/bmc-2021-0004
DO - 10.1515/bmc-2021-0004
M3 - Article
C2 - 33991468
SN - 1868-5021
VL - 12
SP - 27
EP - 35
JO - Biomolecular Concepts
JF - Biomolecular Concepts
IS - 1
ER -